STOCK TITAN

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences clinical trial
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) will present topline clinical data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting. The data includes results from the Phase 1/2 trial of SNS-101, a human monoclonal antibody targeting the immune checkpoint VISTA. The presentation will cover monotherapy and combination dose escalation portions of the trial, focusing on patients with advanced solid tumors. The poster presentation will take place on June 1, 2024, in Chicago, IL.
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) presenterà i dati clinici principali dello studio di fase I sull'aumento del dosaggio di SNS-101 durante l'incontro annuale dell'ASCO del 2024. I dati includono i risultati del trial di fase 1/2 di SNS-101, un anticorpo monoclonale umano che prende di mira il checkpoint immunitario VISTA. La presentazione tratterà le parti del trial relative all'aumento del dosaggio sia in monoterapia che in combinazione, concentrandosi sui pazienti con tumori solidi avanzati. La presentazione del poster si svolgerà il 1 giugno 2024 a Chicago, IL.
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) presentará los datos clínicos principales del estudio de escalada de dosis de la Fase I de SNS-101 en la Reunión Anual de ASCO 2024. Los datos incluyen los resultados del ensayo de fase 1/2 de SNS-101, un anticuerpo monoclonal humano que se dirige al punto de control inmunitario VISTA. La presentación abarcará las partes de escalada de dosis en monoterapia y en combinación del ensayo, enfocándose en pacientes con tumores sólidos avanzados. La presentación de pósters será el 1 de junio de 2024, en Chicago, IL.
Sensei Biotherapeutics, Inc. (나스닥: SNSE)는 2024년 ASCO 연례 미팅에서 SNS-101 1상 용량 증량 연구의 최상위 임상 데이터를 발표할 예정입니다. 이 데이터에는 면역 체크포인트 VISTA를 대상으로 한 인간 단클론 항체인 SNS-101의 1/2상 시험 결과가 포함됩니다. 발표는 단독 요법 및 조합 요법 용량 증량 부분을 다루며, 진행성 고형 종양 환자에 초점을 맞출 것입니다. 포스터 발표는 2024년 6월 1일 시카고, IL에서 진행됩니다.
Sensei Biotherapeutics, Inc. (Nasdaq : SNSE) présentera les données cliniques principales de l'étude de phase I sur l'escalade des doses de SNS-101 lors de la réunion annuelle de l'ASCO en 2024. Les données incluent les résultats de l'essai de phase 1/2 sur SNS-101, un anticorps monoclonal humain ciblant le point de contrôle immunitaire VISTA. La présentation couvrira les parties de l'essai sur l'escalade des doses en monothérapie et en combinaison, se concentrant sur les patients atteints de tumeurs solides avancées. La présentation par affiche aura lieu le 1er juin 2024 à Chicago, IL.
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) wird auf der ASCO-Jahrestagung 2024 die obersten klinischen Daten aus der Dosis-Eskalationsstudie der Phase I zu SNS-101 vorstellen. Die Daten beinhalten Ergebnisse der Phase-1/2-Studie zu SNS-101, einem humanen monoklonalen Antikörper, der sich gegen den Immuncheckpoint VISTA richtet. Die Präsentation wird sich auf die Teile der Studie konzentrieren, die sowohl die Dosis-Eskalation in Monotherapie als auch in Kombination betreffen, speziell bei Patienten mit fortgeschrittenen soliden Tumoren. Die Posterpräsentation findet am 1. Juni 2024 in Chicago, IL statt.
Positive
  • None.
Negative
  • None.

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), will be presented in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024.

Presentation Details:

Title: Initial results from a first-in-human phase 1 study of SNS-101 (pH-selective anti-VISTA antibody) alone or in combination with cemiplimab in patients with advanced solid tumors
Presenter: Dr. Shiraj Sen
Session Type: Poster Session
Session Title: Developmental Therapeutics—Immunotherapy
Date and Time: Saturday, June 1, 2024, at 9:00 a.m. – 12:00 p.m. CDT
Abstract Number: 2600

About Sensei Biotherapeutics 
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn

Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe”, “designed to,” “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Sensei’s current beliefs and expectations. These forward-looking statements include expectations regarding the development, potential therapeutic benefits and safety profile of Sensei’s product candidates, including SNS-101. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Sensei’s product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Sensei’s product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Sensei’s product candidates; the risk that Sensei’s product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that Sensei anticipates; risks associated with Sensei’s dependence on third-party suppliers and manufacturers, including sole source suppliers, over which Sensei may not always have full control; risks regarding the accuracy of Sensei’s estimates of expenses, capital requirements and needs for additional financing; and other risks and uncertainties that are described in Sensei’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on or about February 29, 2024 and Sensei’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Sensei as of the date of this release, and Sensei assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com

Media Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com


FAQ

What clinical data will Sensei Biotherapeutics present at the 2024 ASCO Annual Meeting?

Sensei Biotherapeutics will present topline clinical data from the SNS-101 Phase I Dose Escalation Study.

What is the focus of the Phase 1/2 trial of SNS-101?

The Phase 1/2 trial of SNS-101 focuses on a human monoclonal antibody targeting the immune checkpoint VISTA.

When will the poster presentation take place?

The poster presentation will take place on Saturday, June 1, 2024, at 9:00 a.m. – 12:00 p.m. CDT in Chicago, IL.

What type of tumors are included in the trial?

The trial includes patients with advanced solid tumors.

What is the abstract number of the presentation?

The abstract number is 2600.

Sensei Biotherapeutics, Inc.

NASDAQ:SNSE

SNSE Rankings

SNSE Latest News

SNSE Stock Data

11.06M
16.54M
34.39%
8.81%
0.77%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
ROCKVILLE